NCT00396266 · MORE INFO

Limitations, agreements, and source contact

AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF · Source last updated 2014-03-07

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

other Details: In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

organization: Genzyme Corporation
phone: 800-745-4447
title: Genzyme Medical Information

Complete source fields

certain Agreement

other Details: In multi-site studies, PI can publish after Genzyme publishes or 18 months after study completion. PI gives Genzyme a draft 60 days before publication. Genzyme can ask that confidential information be removed, and can defer publication another 60 days upon notifying PI that it will file a patent application on inventions contained in the draft.
pi Sponsor Employee: false
restriction Type: OTHER
restrictive Agreement: true

point Of Contact

organization: Genzyme Corporation
phone: 800-745-4447
title: Genzyme Medical Information

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice